Hand exercises for patients with rheumatoid arthritis: an extended follow-up of the SARAH randomised controlled trial by Williamson, E et al.
Hand exercises for patients with
rheumatoid arthritis: an extended
follow-up of the SARAH randomised
controlled trial
Esther Williamson,1 Christopher McConkey,2 Peter Heine,1 Sukhdeep Dosanjh,2
Mark Williams,3 Sarah E Lamb1,2
To cite: Williamson E,
McConkey C, Heine P, et al.
Hand exercises for patients
with rheumatoid arthritis: an
extended follow-up of the
SARAH randomised
controlled trial. BMJ Open
2017;7:e013121.
doi:10.1136/bmjopen-2016-
013121
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2016-013121).
Received 5 October 2016
Revised 23 November 2016
Accepted 13 December 2016
For numbered affiliations see
end of article.
Correspondence to
Dr Esther Williamson; esther.
williamson@ndorms.ox.ac.uk
ABSTRACT
Objectives: The Stretching And strengthening for
Rheumatoid Arthritis of the Hand (SARAH)
randomised controlled trial evaluated the effectiveness
of a hand exercise programme and demonstrated
it was clinically effective and cost-effective at
12 months. The aim of this extended follow-up was
to evaluate the effects of the SARAH programme
beyond 12 months.
Methods: Using postal questionnaires, we collected
the Michigan Hand Questionnaire hand function
(primary outcome), activities of daily living and work
subscales, pain troublesomeness, self-efficacy and
health-related quality of life. All participants were asked
how often they performed hand exercises for their
rheumatoid arthritis. Mean difference in hand function
scores were analysed by a linear model, adjusted for
baseline score.
Results: Two-thirds (n=328/490, 67%) of the original
cohort provided data for the extended follow-up. The
mean follow-up time was 26 months (range 19–
40 months).
There was no difference in change in hand function
scores between the two groups at extended follow-up
(mean difference (95% CI) 1.52 (−1.71 to 4.76)).
However, exercise group participants were still
significantly improved compared with baseline
(p=0.0014) unlike the best practice usual care group
(p=0.1122). Self-reported performance of hand
exercises had reduced substantially.
Conclusions: Participants undertaking the SARAH
exercise programme had improved hand function
compared with baseline >2 years after randomisation.
This was not the case for the control group. However,
scores were no longer statistically different between the
groups indicating the effect of the programme had
diminished over time. This reduction in hand function
compared with earlier follow-up points coincided with
a reduction in self-reported performance of hand
exercises. Further intervention to promote long-term
adherence may be warranted.
Trial registration number: ISRCTN89936343;
Results.
INTRODUCTION
Rheumatoid arthritis (RA) is the most common
inﬂammatory polyarthritis.1 Hand dysfunction
is common and to address this, exercises are
recommended.2 3 Recommendations include
exercises for enhancing ﬂexibility, muscle
strength and managing functional impair-
ments.2 Limited evidence of the effectiveness
of hand exercises for people with RA4–8 led to
the commissioning of the Stretching and
Strengthening for Rheumatoid Arthritis of the
Hand (SARAH) trial (ISRCTN89936343).9 10
The SARAH trial demonstrated that an in-
dividually tailored, progressive stretching and
strengthening hand exercise programme
improved hand function and was cost effective
compared with usual care over a 12-month
period.11 12 However, there remained a lack
of evidence regarding the long-term effect of
hand exercises.
Strengths and limitations of this study
▪ There was a lack of evidence regarding the long-
term effectiveness of hand exercises for improv-
ing hand function in patients with rheumatoid
arthritis (RA) beyond 12 months.
▪ This paper reports on the extended follow-up
(average follow-up of 26 months) of a trial evalu-
ating the effectiveness of an individually tailored,
progressive stretching and strengthening hand
exercise programme for people with RA.
▪ The benefits of the exercises evident at
12 months follow-up had reduced but not com-
pletely diminished, however, so had adherence
with the exercise programme.
▪ This study highlights the importance of support-
ing patients with RA to maintain regular exercise.
▪ The extended follow-up was not planned at the
start of the trial so the response rate is lower
than that of the main trial.
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Adherence to any exercise programme is crucial.13
Support provided by health professionals enhances
adherence with exercises but adherence is challenging
when unsupervised.14 The SARAH exercise programme
was prescribed by a physiotherapist or occupational
therapist who provided a maximum of six supervisory
sessions during a 3-month period. The median number
of sessions actually attended by participants was 5 (IQR
5–6). During the sessions, exercises were tailored to
ensure maximal effect, and adherence promoted using
a well-recognised behavioural framework.15 It was
intended that participants would carry out exercises
daily at home during and beyond the supervised period.
The aim of the extended follow-up study was to esti-
mate adherence to the intervention after the 3-month
supervisory period, and the clinical effects of the
SARAH exercise programme beyond 12 months.
METHODS
Study design
A pragmatic, multicentre, randomised controlled trial
carried out in 17 National Health Service (NHS) hospi-
tals in the UK.11
Participants
Participants were adults (≥18 years) with RA affecting
their hands, who were either not on a disease-modifying
antirheumatic drugs (DMARD) regime or who had
been on a stable DMARD regimen (including biologic
agents) for 3 months or more. RA was deﬁned using the
American College of Rheumatology criteria.16 People
who had upper limb surgery or fracture in the previous
6 months, were waiting for upper limb surgery or were
pregnant were excluded.
Study procedures
Potential participants were approached during clinic
visits or from clinic records (October 2009 to May 2011)
and provided with a written invitation and information
sheet. A researcher arranged an appointment to discuss
the trial, check eligibility and if appropriate, complete
baseline assessments and randomise participants.
Follow-up data was collected 4 and 12 months after ran-
domisation at face-to-face appointments. The extended
follow-up (>12 months) was an addition to the original
study protocol.9 Extended follow-up questionnaires were
posted to all participants (unless they had withdrawn
from the study or were deceased) between September
2012 and January 2013 so the time for extended
follow-up varied between participants. Informed consent
was provided by all participants. Participants who agreed
to participate in the extended follow-up completed a
response form indicating their consent and returned this
with their questionnaire. Participants could request to
complete the questionnaire over the phone. If partici-
pants did not respond to the extended follow-up invita-
tion, one reminder letter was sent.
Interventions
The control intervention was best practice usual care con-
sisting of joint protection education, advice on whole
body mobility exercises and, if appropriate, functional
splinting delivered over a maximum of three appoint-
ments. Participants in the intervention arm received best
practice usual care and an individually tailored exercise
programme, in which moderate-intensity to high-intensity
strengthening and stretching exercises were prescribed.
Therapists used supervisory sessions to provide advice,
check tolerability, progress or regress exercises and
promote adherence. Treatments are described in detail
elsewhere.10
Data collection
Baseline measures
Measurements collected at baseline are described else-
where.12 These included demographics, Michigan Hand
Outcome Questionnaire (MHQ),17–19 pain troublesome-
ness,20 Arthritis Self-efﬁcacy Scale,21 the EuroQol ﬁve
dimensions questionnaire (EQ5D),22 the 12-item Short
Form Health Survey (SF-12),23 impairment (grip
strength, dexterity, hand and wrist range of motion and
joint alignment), erythrocyte sedimentation rate (ESR),
C reactive protein (CRP), modiﬁed tender and swollen
joint count of the hands and wrist24 and medication use.
Outcome measures
We reduced the number of outcomes included in the
extended follow-up because of the postal mode of
administration. Data collection was limited to self-
reported measures and we were not able to include phys-
ical measures such as strength and dexterity that were
measured at previous follow-up time points. To reduce
participant burden, we did not use the whole MHQ and
excluded lengthy health resource use questions.
Outcome measures for the main trial are described in
detail elsewhere.11
We collected the primary outcome (MHQ hand func-
tion subscale) for which scores ranged from 0 to 100, with
higher scores indicating better performance. Secondary
outcomes were the activities of daily living (ADL) and
work MHQ subscales, pain troublesomeness,20
participant-rated improvement, Arthritis Self-efﬁcacy,21 the
EuroQol EQ5D22 and the SF-12.23 To assess adherence
with the exercise programme, all participants were asked
to report how often they performed hand exercises for
their RA.
Sample size estimates
The SARAH trial was sized to detect a small to moderate
effect size of 0.3 in the primary outcome at 12 months.
This was based on a previous smaller efﬁcacy study of
exercise that reported a standardised difference of 0.4
(8). We modiﬁed this effect downward (to 0.3) to
account for the SARAH trial being a pragmatic multi-
centre trial and to reﬂect worthwhile effects found in
other pragmatic studies of RA.25 To show this difference
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with 80% power at the 5% signiﬁcance level, we required
data on a total of 352 participants (using SAS procedure
GLMPOWER) for analysis. Allowing for a 25% loss to
follow-up, at least 469 participants were needed.
Randomisation
We used a central telephone randomisation service at
the Warwick Clinical Trials Unit. Randomisation was
stratiﬁed by centre, and used a variable block length.
Allocation was computer generated and revealed once
the participant was registered into the trial. It was not
possible to blind participants and therapists delivering
treatments to treatment allocation but follow-up data was
collected by blinded research staff.
Statistical analysis
The analysis was intention to treat. Descriptive statistics
were generated to compare people completing extended
follow-up and those not, and the characteristics of ran-
domised groups to identify any selection and retention
biases. We only report earlier outcomes (baseline, 4 and
12 months) for those participants that took part in the
extended follow-up. For all outcomes, we estimated
within-group and between-group differences at each
time point (as well as overall) using a linear model.
Estimates of treatment effect were reported as the mean
difference and 95% CI. All models were adjusted for
baseline MHQ score and prerandomisation drug regime
(biologic DMARDs, combination non-biologic DMARDs,
single non-biologic DMARD and no DMARD). The
inclusion of time-to-follow-up allowed adjustment for
variable amounts of follow-up, and an estimation of the
impact of duration of follow-up on the treatment effect.
Multiple imputation estimates for MHQ overall hand
function were also calculated for the extended follow-up
time point and adjusted for hospital, age and sex. The
multiple imputations took account of the MHQ hand
function score for all time points and baseline data (age,
CRP, ESR, SF-12 physical and mental summary scores,
pain troublesomeness, conﬁdence, impairment measure-
ments and DMARD group).
Secondary outcome measures of change in pain,
quality of life and self-efﬁcacy were analysed in a similar
manner. Patient-rated improvement was compared using
the Wilcoxon test. Report of current exercise perform-
ance was categorised as at least three times per week,
less than three times per week and no exercise and was
analysed using Pearson’s χ2.
Statistical analyses used SAS V.9.2 software (SAS
Institute, USA).
RESULTS
Characteristics of the sample
The baseline characteristics are given in table 1. Just
over two-thirds of the original cohort (n=32 867 %)
provided data (ﬁgure 1). On average, participants com-
pleted the extended follow-up 26 months after
randomisation, with no difference between the groups
(exercise: median time of 25.8 months (IQR 22.0–30.8);
best practice usual care: median time of 26 months
(IQR 22.2–29.9); p=0.6522). An analysis performed to
see if the time of extended follow-up (which varied from
19–40 months after randomisation) was associated with
outcome showed there was no signiﬁcant time effect
(p=0.1399).
The two groups at extended follow-up were similar in
age, gender, disease duration and baseline EQ-5D
scores.
The characteristics of participants who did and did
not respond to the extended follow-up are provided in
table 1. The average age of responders was 63.6 years
(SD 10.9) and 75.6% (248/328) were women, which was
similar to the demographic of the entire sample at base-
line. However, non-responders had worse hand function
at baseline than responders (scores 48.1 and 54.0,
respectively). The proportion of participants reporting
that they were performing hand exercises for their RA at
earlier follow-up points was higher among responders
compared with non-responders (table 1) although the
difference was not statistically signiﬁcant (p=0.1323 and
p=0.2598). Most notably, a greater proportion of non-
responders in the exercise arm reported doing no exer-
cise at 12 months compared with those who responded
(44.4% vs 24.5%, respectively; p=0.0488).
Intervention adherence
Exercise programme participants reported substantially
reducing their frequency of hand exercises over time
with 71.4% reporting that they exercised three times per
week at 4 months and only 31.4% at the extended
follow-up (table 2). They had reported performing hand
exercises for their RA more frequently than best practice
usual care participants at the 4 and 12 months follow-up.
At extended follow-up, there was no longer a clear differ-
ence between the two groups in their reports of hand
exercises.
Primary outcome—hand function
Figure 2 and table 3 show the change in MHQ hand
function subscale scores over time for those completing
the extended follow-up. Best practice usual care resulted
in small but statistically signiﬁcant improvements in
hand function at 4 and 12 months, in comparison with
baseline values. However, the within-group difference
between baseline and extended follow-up was not statis-
tically signiﬁcant (mean MHQ hand function subscale
score at baseline =54.1 (SD=15.65); extended follow-up
=56.1 (SD=18.85); p=0.1122).
Exercise resulted in substantial improvements from base-
line, with the peak effect at 4 months. For 4 and
12 months, differences between the exercise and best prac-
tice usual care group were statistically and clinically signiﬁ-
cant. By the extended follow-up time point, the exercise
intervention was still associated with a signiﬁcant
within-group improvement in hand function in
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Table 1 Characteristics of participants completing and not completing the extended follow-up by arm
Characteristic
by arm
Participants
completing the
extended
follow-up
Participants not
completing the
extended follow-up
Participants
completing the
extended follow-up
Participants not
completing the
extended follow-up
Participants
completing the
extended follow-up
Participants not
completing the
extended
follow-up
Study arm Exercise programme Usual care Combined
Age at randomisation, mean (SD) 62.9 (11.0) 58.6 (14.0) 64.3 (10.8) 61.5 (12.1) 63.6 (10.9) 59.8 (13.2)
Sex, F (%) 77.4 74.7 74.0 81.2 75.6 77.5
Ethnic origin, n (%)
White 85 (93.4) 153 (98.7) 66 (95.7) 169 (98.3) 151 (93.4) 322 (98.5)
Indian 2 (2.2) 1 (0.7) – 2 (1.2) 2 (1.3) 3 (0.9)
Pakistani – – 1 (1.5) – 1 (0.6) –
Mixed 2 (2.2) 1 (0.7) 1 (1.5) – 3 (1.9) 1 (0.3)
Other 2 (2.2) – 1 (1.5) 1 (0.6) 3 (1.9) 1 (0.3)
Disease duration (years), mean (SD) 12.4 (10.8) 14.4 (10.4) 14.7 (12.5) 12.4 (10.7) 13.7 (11.8) 13.5 (10.6)
Baseline ESR Median (IQR) 13.0 (7.0, 26.0) 21.0 (9.0,30.0) 17.0 (9.0, 30.0) 13.0 (8.0, 27.0) 15.0 (8.0,28.0) 18.5 (8.0, 28.5)
Baseline CRP Median (IQR) 5.0 (3.0,11.0) 6.5 (3.0,13.0) 6.0, (3.0,13.0) 6.0 (3.0, 11.0) 5.0 (3.0, 12.0) 6.0 (3.0, 12.0)
Medications, n (%)
Biologic DMARD 30 (19.4) 22 (24.2) 35 (20.2) 17 (24.6) 65 (19.8) 39 (24.4)
Combination non-biologic DMARD 46 (29.7) 26 (28.6) 42 (24.3) 11 (15.9) 42 (26.8) 37 (23.1)
Single non-biologic DMARD 66 (42.6) 37 (40.7) 85 (49.1) 33 (47.8) 85 (46.0) 70 (43.8)
Other medications 13 (8.4) 6 (6.6) 11 (6.4) 8 (11.6) 11 (3.4) 14 (8.8)
Baseline MHQ hand function, mean (SD) 53.9 (15.1) 48.9 (14.8) 54.1 (15.6) 47.0 (17.4) 54.0 (15.4) 48.1 (15.9)
Baseline SF-12 physical summary score, mean (SD) 35.4 (9.7) 31.1 (9.4) 35.4 (9.7) 32.1 (8.5) 35.4 (9.7) 31.5 (9.0)
Baseline SF-12 mental summary score, mean (SD) 49.7 (10.5) 45.5 (10.7) 50.4 (10.4) 45.1 (11.7) 50.1 (10.4) 45.3 (11.1)
Baseline EQ5D health state, mean (SD) 0.6 (0.3) 0.5 (0.3) 0.6 (0.2) 0.5 (0.3) 0.6 (0.3) 0.5 (0.3)
Baseline pain troublesomeness score, mean (SD) 43.1 (20.5 50.9 (24.2) 46.0 (21.1) 54.6 (21.6) 44.6 (20.9) 52.5 (23.1)
Baseline self-efficacy—confidence to manage their
condition, mean (SD)
69.5 (18.2) 62.5 (23.0) 71.3 (17.7) 62.2 (21.0) 70.5 (17.9) 62.4 (22.1)
Participant reported frequency
of hand exercises at 4 months, n (%)
At least 3 times a week 107 (71.8) 44 (67.7) 80 (48.2) 25 (45.5) 187 (59.4) 69 (57.5)
<3 times a week 26 (17.5) 11 (16.9) 36 (21.7) 5 (9.1) 62 (19.7) 16 (13.3)
No exercises 16 (10.7) 10 (15.4) 50 (30.1) 25 (45.5) 66 (21.0) 35 (29.2)
Participant-reported frequency
of hand exercises at 12 months, n (%)
At least 3 times a week 61 (40.4) 18 (33.3) 66 (39.1) 18 (38.3) 127 (39.7) 36 (35.6)
<3 times a week 53 (35.1) 12 (22.2) 35 (20.7) 9 (19.1) 88 (27.5) 21 (20.8)
No exercises 37 (24.5) 24 (44.4) 68 (40.2) 20 (42.6) 105 (32.8) 44 (43.6)
Change in MHQ hand function baseline to
12 months, mean (SD)
7.2 (13.6) 9.8 (16.8) 3.2 (16.0) 4.8 (16.3) 5.1 (15.0) 7.5 (16.7)
Change in SF-12 physical summary score baseline
to 12 months, mean (SD)
0.8 (7.2) 2.3 (6.3) –0.1 (7.6) 0.5 (6.7) 0.3 (7.5) 1.5 (6.5)
Change in SF-12 mental summary score baseline to
12 months, mean (SD)
2.1 (9.9) 2.4 (12.4) 0.2 (9.5) 1.1 (10.8) 1.1 (9.7) 1.8 (11.7)
Change in EQ5D health state baseline to 12 months,
Mean (SD)
0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.3) 0.0 (0.2) 0.0 (0.3)
CRP, C reactive protein; DMARD, disease-modifying antirheumatic drugs; EQ5D, EuroQol five dimensions questionnaire, MHQ, Michigan Hand Outcome Questionnaire.
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Figure 1 Consolidated Standards of Reporting Trials Flow diagram.
Table 2 Participant-reported frequency of hand exercises for their RA (n (%)) for those that responded to the extended
follow-up
4 months 12 months Extended follow-up
Usual care
Exercise
programme Usual care
Exercise
programme Usual care
Exercise
programme
n=169 n=152 n=171 n=155 n=173 n=155
Participant-reported frequency of hand exercises
At least three times a week 80 (48.2) 107 (71.8) 66 (39.1) 61 (40.4) 60 (34.9) 48 (31.4)
Less than three times a week 36 (21.7) 26 (17.5) 35 (20.7) 53 (35.1) 38 (22.1) 48 (31.4)
No exercises 50 (30.1) 16 (10.7) 68 (40.2) 39 (24.5) 74 (43.0) 57 (37.3)
Not answered 3 3 2 2 1 2
p trend (Wilcoxon) <0.0001 0.0884 0.7715
RA, rheumatoid arthritis.
Williamson E, et al. BMJ Open 2017;7:e013121. doi:10.1136/bmjopen-2016-013121 5
Open Access
group.bmj.com on June 22, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
Figure 2 Mean change from baseline over time for the primary and secondary outcomes for those who responded to the
extended follow-up. Error bars represent the SE. For the number of participants providing data for each outcome at each time
point, please refer to table 3.
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Table 3 Estimates of effect in primary outcome and patient-reported secondary outcome measures for those who responded to the extended follow-up
Mean change from baseline (95% CI) Mean treatment
difference (95% CI) p Value
Number of
participants confirmedUsual care Exercise programme
MHQ overall hand function
4 months 3.27 (1.15 to 5.39) 9.27 (7.19 to 11.34) 6.24 (3.56 to 8.92)*** <0.0001 320
12 months 3.19 (0.79 to 5.59) 7.18 (5.02 to 9.33) 3.91 (0.71 to 7.10)* 0.0171 324
Extended follow-up 1.97 (−0.45 to 4.39) 3.76 (1.50 to 6.02) 1.52 (−1.71 to 4.76) 0.3567 327
MHQ ADL (both hands)
4 months 3.37 (0.94 to 5.79) 8.29 (5.61 to 10.96) 5.07 (1.73 to 8.42)** 0.0032 319
12 months 2.53 (−0.12 to 5.18) 5.34 (2.71 to 7.97) 2.83 (−0.90 to 6.56) 0.1375 323
Extended follow-up 2.34 (0.03 to 4.66) 3.15 (0.30 to 6.01) 0.72 (−2.88 to 4.32) 0.6948 324
MHQ work
4 months 4.91 (1.91 to 7.91) 8.26 (5.47 to 11.04) 3.04 (−0.96 to 7.04) 0.1370 316
12 months 2.97 (−0.05 to 5.99) 7.70 (4.73 to 10.68) 4.44 (0.30 to 8.57)* 0.0363 323
Extended follow-up 5.81 (2.97 to 8.65) 7.76 (4.67 to 10.84) 2.06 (−2.10 to 6.22) 0.3318 315
SF 12 Mental Component Score (MCS)
4 months 0.70 (−0.62 to 2.02) 1.09 (−0.18 to 2.37) 0.51 (−1.16 to 2.18) 0.5488 319
12 months 0.21 (−1.21 to 1.64) 2.12 (0.54 to 3.69) 1.63 (−0.22 to 3.49) 0.0857 322
Extended follow-up 0.21 (−1.23 to 1.66) 0.27 (−1.25 to 1.78) 0.22 (−1.71 to 2.15) 0.8252 326
SF 12 Physical Component Score (PCS)
4 months 0.62 (−0.39 to 1.63) 1.84 (0.65 to 3.02) 1.37 (−0.12 to 2.86) 0.0719 319
12 months −0.09 (−1.24 to 1.06) 0.76 (−0.39 to 1.92) 0.72 (−0.79 to 2.23) 0.3519 321
Extended follow-up −0.51 (−1.66 to 0.64) 0.19 (−1.16 to 1.54) 0.50 (−1.24 to 2.25) 0.5720 326
EQ-5D health state
4 months 0.0 (−0.03 to 0.04) 0.06 (0.02,0.09) 0.03 (−0.01 to 0.07) 0.1654 319
12 months 0.02 (−0.02 to 0.05) 0.04 (0.00 to 0.07) 0.00 (−0.04 to 0.05) 0.8239 0.322
Extended follow-up −0.01 (−0.05 to 0.02) −0.01 (−0.05 to 0.03) −0.01 (−0.06 to 0.04) 0.6893 324
Pain troublesomeness score†
4 months −4.79 (−7.76 to −1.82) −5.57 (−8.25 to −2.90) −2.51 (−6.22 to 1.21) 0.1872 315
12 months −4.68 (−7.83 to −1.53) −5.03 (−8.16 to −1.90) −1.58 (−5.65 to 2.48) 0.4454 322
Extended follow-up −3.79 (−6.93 to −0.64) 0.20 (−2.98 to 3.38) 3.23 (−0.83 to 7.28) 0.1199 326
Self-efficacy—confidence to manage their condition
4 months 2.38 (−0.15 to 4.62) 6.58 (3.74 to 9.42) 3.41 (0.5 to 6.29)* 0.0209 319
12 months 1.30 (−1.32 to 3.92) 5.46 (2.29 to 8.62) 3.19 (0.71 to 6.98) 0.1113 321
Extended follow-up 0.22 (−2.34 to 2.78) 2.96 (0.03 to 5.90) 2.30 (−1.20 to 5.79) 0.1988 323
*p<0.05; ** p<0.01; ***p<0.001.
†Higher score, more pain.
ADL, activities of daily living; EQ-5D, EuroQol five dimensions questionnaire; MHQ, Michigan Hand Outcome Questionnaire.
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comparison with baseline (mean MHQ hand function sub-
scale score at baseline =53.9 (SD=15.1); extended
follow-up=57.7 (SD=18.04); p=0.0014). However, the differ-
ence between exercise and best practice usual care inter-
ventions was no longer statistically signiﬁcant (table 3).
Secondary outcomes
MHQ ADL and MHQ work subscales
Signiﬁcant within-group differences were observed in
both groups for the MHQ ADL and MHQ work sub-
scales at the extended follow-up compared with baseline
(p<0.05 and p<0.001 for best practice usual care and the
exercise arms, respectively). Greater improvement from
baseline was seen in the exercise arm (ﬁgure 2 and
table 3).
There was a statistically signiﬁcant between-group dif-
ference in the MHQ ADL subscale at 4 and 12 months
and the MHQ work subscale at 12 months favouring the
exercise arm but this difference was no longer signiﬁ-
cant at the extended follow-up.
Health-related quality of life (SF-12 and EQ-5D)
There were no observable within-group differences or
between-group differences at any follow-up time point as
measured by the SF-12 or the EQ-5D (ﬁgure 2 and table 3).
Pain troublesomeness
There were statistically signiﬁcant within-group changes
at the 4 and 12 months follow-up with both groups
reporting less pain compared with baseline and this con-
tinued in the best practice usual care arm at extended
follow-up (p=0.0196). However, the pain scores reported
at extended follow-up in the exercise arm were similar
to baseline scores (p=0.9039).
There was no statistically signiﬁcant between-group dif-
ference in pain troublesomeness scores at any follow-up
time point (ﬁgure 2 and table 3).
Self-efficacy
At extended follow-up, there was a signiﬁcant
within-group change in self-efﬁcacy observed in the
exercise arm but not the best practice usual care arm.
Participants in the exercise group reported higher self-
efﬁcacy scores compared with their baseline scores
(p=0.0496) but this was not the case for the best practice
usual care (p=0.8675).
Respondents in the exercise arm reported higher self-
efﬁcacy scores at 4 months follow-up compared with the
best practice usual care group but this difference was
diminished at 12 months and extended follow-up so the
between-group difference was no longer evident (ﬁgure 2
and table 3).
Participant-rated improvement
Participant-rated improvement in the exercise arm were
signiﬁcantly higher at 4 and 12 months follow-up than
the best practice usual care group but there was no dif-
ference between the two groups at the extended
follow-up (table 4).
Multiple imputation
Multiple imputation was used to evaluate the impact of
missing data and the estimate of treatment difference
from baseline to extended follow-up was 1.75 (–1.20,
4.70), p=0.2433. This is similar to the non-imputed ana-
lysis suggesting that missing data was not a major inﬂu-
ence on the study ﬁndings.
DISCUSSION
We have evaluated the long-term outcomes of an indi-
vidually tailored exercise programme compared with
best practice usual care for adults with RA of the hand.
Between-group differences had diminished over an
average follow-up time of 26 months but generally
functional scores favoured the exercise group. Both
groups had improved hand function compared with
baseline but this was only statistically signiﬁcant in the
exercise group. We interpret this to mean that
although functional improvements due to the exercises
had reduced, they had not diminished completely.
Exercise arm participants completed treatment with
Table 4 Patient-reported secondary outcome measures (n (%)) for those that responded to the extended follow-up
4 months 12 months Extended follow-up
Usual care
Exercise
programme Usual care
Exercise
programme
Usual
care
Exercise
programme
n=167 n=149 n=170 n=151 n=172 n=153
Participant-rated improvement
Completely recovered 1 (0.6) – 2 (1.2) 1 (0.7) 1 (0.6) –
Much improved 18 (10.8) 34 (22.8) 14 (8.2) 31 (20.5) 22 (12.8) 25 (16.3)
Slightly improved 34 (20.4) 48 (32.2) 23 (13.5) 38 (25.2) 17 (9.9) 24 (15.7)
No change 65 (38.9) 45 (30.2) 69 (40.6) 47 (31.1) 75 (43.6) 58 (37.9)
Slightly worsened 41 (24.6) 17 (11.4) 49 (28.8) 22 (14.6) 41 (23.8) 35 (22.9)
Much worsened 8 (4.8) 5 (3.4) 12 (7.1) 9 (6.0) 15 (8.7) 7 (4.6)
Vastly worsened – – 1 (0.6) 3 (2.0) 1 (0.6) 4 (2.6)
p trend (Wilcoxon) <0.0001 <0.0001 0.2018
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their therapist ∼3 months after randomisation, so for
some participants it had been 2 years since attending
treatment. Therefore, it is very encouraging that some
beneﬁts still persisted. We aimed to estimate exercise
adherence beyond the supervised period and the data
shows that by the extended follow-up, many partici-
pants in the exercise arm were no longer exercising as
intended. RA is a progressive disease, so regular exer-
cise of sufﬁcient intensity is needed to maintain
muscle strength. It is likely that participants were no
longer achieving a sufﬁcient dose to maintain func-
tional improvements.
Another study of upper limb exercises demon-
strated a similar reduction of beneﬁt over time
where gains observed at 12 weeks were no longer
evident at 26 weeks follow-up26 with an assumption it
was due to reduced adherence but this data was not
collected.
Another proposed mechanism by which the interven-
tion improved function was by bolstering self-efﬁcacy.
This effect had also diminished which may be due to
the fact it had been 2 years since attending treatment.
One outcome favoured the best practice usual care (pain
troublesomeness scores). There were no between-group dif-
ferences but the best practice usual care group had a small
but statistically signiﬁcant reduction in pain compared with
baseline unlike the exercise group. However, the reduction
in pain was small and we are conﬁdent the exercises did
not increase pain while improving function. There was no
difference in adverse events reported11 and we conclude
that the exercise programme is safe.
Clinical implications and further research
The SARAH exercise programme is an effective adjunct
to the medical management of RA for patients with
hand problems, but the beneﬁt from the exercise pro-
gramme did reduce over time as participants reported
doing less exercises. These ﬁndings raise important
questions regarding how patients might be supported to
exercise long term which is probably necessary to main-
tain functional gains.
Further research is needed to establish how ongoing
support could be provided. Patients with RA are seen
frequently in rheumatology outpatient clinics with the
National Institute for Health and Care Excellence
recommending annual reviews for patients with RA.27
Staff could monitor patient’s exercise participation
during these appointments. However, there is uncer-
tainty among health professionals about providing
advice about exercise to patients with RA.28 29 Specialist
rheumatology nurses play an important role in monitor-
ing and supporting patients, yet, the European League
Against Rheumatism (EULAR) recommendations for
specialist rheumatology nurses do not mention exer-
cise.30 There is a need to educate health professionals
and patients about the importance of regular exercise. It
is safe for patients with RA to exercise26 31 and health
professionals need to be conﬁdent to advise on exercise
regimes, referring to therapists when needed.
Consideration should be given to how we can ensure all
health professionals who see patients with RA can
encourage adherence to exercise, for example, nurses
or therapists working within primary care settings and
not just specialist rheumatology clinics.
Patients with RA have to continually modify their treat-
ment in response to changes in their condition. This
also applies to exercise which presents another chal-
lenge. The SARAH programme is manualised, with clear
instructions for progressing/regressing exercises allow-
ing patients to modify exercises when needed.
Participant feedback was that this was easy to follow12 so
these types of resources could be made available to
health professionals and patients to help patients to
exercise regularly.
Methodological limitations
The response rate was lower than the main study. This
was not unexpected as this follow-up was not planned at
the outset of the study so participants were unaware they
would receive the postal questionnaire. We only contacted
participants by post so as not to place undue pressure on
them to respond and only phoned those who requested
to complete the questionnaire by phone. As a conse-
quence, the analysis is underpowered to detect a differ-
ence in the primary and secondary outcomes. Loss to
follow-up could introduce bias and there were some dif-
ferences in responders and non-responders, but these
were equal across treatment groups. Most notably, non-
responders had poorer hand function at baseline and
reported lower levels of exercise adherence at earlier
follow-up especially in the exercise arm. It could be
expected that responders would have better outcomes
compared with non-responders resulting in an overesti-
mate of the treatment effect. However, multiple imput-
ation techniques estimated the effect of missing data and
the results were largely similar indicating that missing
data did not overly inﬂuence the ﬁndings. Overall, we are
conﬁdent that the participants providing data were a
good representation of the total cohort. The other factor
that may have inﬂuenced ﬁndings was the disease status
of participants. RA is a ﬂuctuating condition, so disease
status at the time of follow-up may have inﬂuenced out-
comes but this information was not available.
In conclusion, a hand exercise programme is an effect-
ive adjunct to current drug management to improve
hand function. Participants in the exercise group had
improved hand function compared with baseline >2 years
after randomisation. Hand function had reduced over
time which coincided with a reduction in hand exercises
highlighting the importance of promoting long-term
exercise adherence among patients with RA.
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